



# Synthesis of chiral and geometrically defined 5,5-diaryl-2-amino-4-pentenoates: novel amino acid derivatives

Methvin Isaac,\* Abdelmalik Slassi, Kathleen Da Silva and Tao Xin


NPS Allelix Corp., 6850 Goreway Drive, Mississauga, ON, Canada L4V 1V7

Received 27 January 2001; revised 23 February 2001; accepted 1 March 2001

**Abstract**—A novel series of 5,5-diaryl-2-amino-4-pentenoates were synthesized. Chirally defined substrates were obtained efficiently using Oppolzer's sultam as a chiral auxiliary and a palladium-catalyzed stereoselective hydrostannylation. © 2001 Elsevier Science Ltd. All rights reserved.

The 5,5-diaryl-2-amino-4-pentenoate series was developed as a novel class of biologically active molecules targeted towards the recently cloned glycine reuptake transport system, specifically the glycine transporter type-2 (GlyT-2) system. This system is prevalent in the central nervous system and is thought to be involved in the treatment of pain and spasticity.<sup>1</sup> Of particular

interest from this series is the sodium derivative of *E*-2-amino-5-[2,4-difluorophenyl]-5-[4-isopropylphenyl]-4-pentenoic acid (**1**), which was found to be a potent GlyT-2 reuptake inhibitor ( $IC_{50} = 330$  nM) as a racemic mixture. Resolving the racemate indicated that the *S*-enantiomer **2** was the active component of the mixture with an  $IC_{50}$  of 150 nM.



**Scheme 1.** (a) Pd(PPh<sub>3</sub>)<sub>4</sub>, CuI, propargyl alcohol, Et<sub>3</sub>N; (b) Red-Al, I<sub>2</sub>, ether; (c) PBr<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 0°C.

\* Corresponding author.

We wish to report on the synthesis of **1**, highlighting the various regio- and stereoselective control elements utilized.


2,4-Difluoriodobenzene **3a** was subjected to the Sonogashira coupling condition<sup>2</sup> with propargyl alcohol giving the alcohol **4a** (Scheme 1). Treatment of **4a** with Red-Al, followed by quenching with iodine, afforded **5a** in good yield and in a regio- and stereospecific manner.<sup>3</sup> The alcohol functionality of intermediate **4a** was then transformed cleanly into the corresponding bromide **6** using phosphorus tribromide.<sup>4</sup>

The allyl bromide **6a** was used in the allylation of **8**,<sup>5</sup> with LDA as base, to afford the versatile intermediate **9**, which can be reacted with a variety of boronic acids (Scheme 2). Compound **9** was then coupled to 4-isopropylphenylboronic acid under the Suzuki-coupling conditions furnishing **10** in good yield. Trifluoroacetic acid-mediated deprotection, followed by hydrolysis, furnished **1** in good overall yield.<sup>6</sup>


An alternative route to **1** is illustrated in Scheme 3. The propargyl bromide **7b**, prepared according to Scheme 1, was reacted with **8** giving the highly functionalized intermediate **12**. The palladium-catalyzed stereoselective hydrostannylation<sup>7</sup> of **12** provided **13** in 55% yield, which was subsequently treated with iodine to effect a tin to iodine exchange to afford **14** (Scheme 3). The vinyl iodide **13** was immediately treated with 2,4-difluorobenzeneboronic acid to give the Suzuki-coupled product **15**. Deprotection of **15**, followed by base-mediated hydrolysis, provided **1**.

To further determine the effect of the chirality on activity, **1** was resolved using a chiral column of an analytical HPLC and the resolved components were separated (Fig. 1).<sup>8</sup> The absolute stereochemistry of the active enantiomer **2** was confirmed using chemical correlation methods.<sup>9</sup>

Utilizing Oppolzer's bornane-10,2-sultam as a chiral auxiliary, treatment of the sultam-derived *N*-(diphenyl-



**Scheme 2.** (a) LDA, THF, HMPA,  $-78^{\circ}\text{C}$  to rt; (b) Ar<sub>2</sub>-B(OH)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, DME/Na<sub>2</sub>CO<sub>3</sub>, 110 $^{\circ}\text{C}$ ; (c) TFA, H<sub>2</sub>O, CH<sub>2</sub>Cl<sub>2</sub>, rt; (d) 1N NaOH, MeOH.



**Scheme 3.** (a) **8**, LDA, THF, HMPA,  $-78^{\circ}\text{C}$  to rt; (b) Bu<sub>3</sub>SnH, PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, THF; (c) I<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>; (d) Ar<sub>1</sub>-B(OH)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, DME/Na<sub>2</sub>CO<sub>3</sub>, 110 $^{\circ}\text{C}$ ; (e) TFA, H<sub>2</sub>O, CH<sub>2</sub>Cl<sub>2</sub>, rt; (f) 1N NaOH, MeOH.






Figure 1.



Ar<sub>1</sub> = 2,4-Difluorophenyl, Ar<sub>2</sub> = 4-Isopropylphenyl



**Scheme 4.** (a) (i) LDA, THF, HMPA,  $-78^{\circ}\text{C}$ , (ii) **7b**,  $-78^{\circ}\text{C}$  to rt; (b)  $\text{Bu}_3\text{SnH}$ ,  $\text{PdCl}_2(\text{PPh}_3)_2$ , THF; (c)  $\text{I}_2$ ,  $\text{CH}_2\text{Cl}_2$ ; (d)  $\text{Ar}_1\text{-B}(\text{OH})_2$ ,  $\text{Pd}(\text{PPh}_3)_4$ ,  $\text{DME}/\text{Na}_2\text{CO}_3$ ,  $110^{\circ}\text{C}$ ; (e) TFA,  $\text{H}_2\text{O}$ ,  $\text{CH}_2\text{Cl}_2$ , rt; (f) 2.5N LiOH,  $\text{H}_2\text{O}/\text{THF}$ .

methylene)glycinate **20**<sup>10</sup> with the activated organic bromide **7b** affords the monoalkylated intermediate **16** with high diastereoselectivity (only one isomer was observed) (Scheme 4). Regioselective hydrostannation of **15**, followed by tin–iodine, afforded the intermediate **17**, which was then subjected to Suzuki coupling, trifluoroacetic acid-mediated deprotection, followed by lithium hydroxide-mediated hydrolysis of the chiral auxiliary, to give the lithium salt of **2** as the pure *S*-enantiomer.

In conclusion, we have successfully synthesized a novel amino acid **1** from *N*-(diphenylmethylene)glycinate precursors. The synthesis was carried out in a highly regio- and stereodefined fashion, as illustrated by the asymmetric synthesis of **2**. The key highlight of the synthetic strategy is the palladium-catalyzed stereoselective hydrostannylation of the highly functionalized intermediates affording products **1** and **2** in good overall yield.

### Acknowledgements


The authors would like to thank Dr. Shawn Maddaford for his valuable discussions and suggestions.

### References

1. Isaac, M.; Slassi, A.; Da Silva, K.; Arora, J.; McClean, N.; McCallum, K. *Bioorg. Med. Chem. Lett.* **2001**, in press.
2. (a) Cassar, L. *J. Organomet. Chem.* **1975**, *93*, 253; (b) Dieck, A.; Heck, R. *J. Organomet. Chem.* **1975**, *93*, 259; (c) Sonogashira, K.; Tohda, Y.; Hagihara, N. *Tetra-*

*hedron Lett.* **1975**, *50*, 4467.

3. Blanchette, M.; Malamas, M.; Nantz, M.; Roberts, J.; Somfai, P.; Whritenour, D.; Masamune, S. *J. Org. Chem.* **1989**, *54*, 2817.
4. Schlosser, M.; Micheal, D.; Croft, S. *Synthesis* **1996**, 591.
5. For the synthesis of **8** from glycine methylester hydrochloride and benzophenone imine, see: O'Donnell, M.; Polt, R. *J. Org. Chem.* **1982**, *47*, 2663.
6. Spectral data for the sodium salt of **1** (off-white solid). <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ: 7.35 (m, 1H), 7.22 (d, 2H, *J*=8.1 Hz), 7.10 (d, 2H, *J*=8.1 Hz), 6.88 (m, 2H), 5.95 (t, 1H, *J*=6.9 Hz), 3.59 (broad, m, 1H), 2.90 (m, 1H), 2.82 (m, 2H), 1.24 (d, 6H, *J*=7.0 Hz). HRMS (FAB) calcd for C<sub>22</sub>H<sub>20</sub>F<sub>2</sub>NO<sub>2</sub> [M–Na+2H]<sup>+</sup>: 346.16187. Found: 346.16044.
7. Liron, F.; Le Garrec, P.; Alami, M. *Synlett* **1999**, *2*, 246.
8. The chiral purity was determined by HPLC using the CHIROBIOTIC T<sup>TM</sup> (Astec) column purchased from Chromatographic Specialties Inc. and ethanol/water (80:20) as the mobile phase.
9. Lopez, A.; Pleixats, R. *Tetrahedron: Asymmetry* **1998**, *9*, 1967.
- 10.



For the synthesis of **20**, see: (a) Josien, H.; Lavielle, S.; Brunissen, A.; Saffroy, M.; Torrens, Y.; et al. *J. Med. Chem.* **1994**, *37*, 1586; (b) Josien, H.; Martin, A.; Chassing, G. *Tetrahedron Lett.* **1991**, *32*, 6547.